» Articles » PMID: 16519680

Kinetic Study of the HIV-1 DNA 3'-end Processing

Overview
Journal FEBS J
Specialty Biochemistry
Date 2006 Mar 8
PMID 16519680
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The 3'-processing of viral DNA extremities is the first step in the integration process catalysed by human immunodeficiency virus (HIV)-1 integrase (IN). This reaction is relatively inefficient and processed DNAs are usually detected in vitro under conditions of excess enzyme. Despite such experimental conditions, steady-state Michaelis-Menten formalism is often applied to calculate characteristic equilibrium/kinetic constants of IN. We found that the amount of processed product was not significantly affected under conditions of excess DNA substrate, indicating that IN has a limited turnover for DNA cleavage. Therefore, IN works principally in a single-turnover mode and is intrinsically very slow (single-turnover rate constant = 0.004 min(-1)), suggesting that IN activity is mainly limited at the chemistry step or at a stage that precedes chemistry. Moreover, fluorescence experiments showed that IN-DNA product complexes were very stable over the time-course of the reaction. Binding isotherms of IN to DNA substrate and product also indicate tight binding of IN to the reaction product. Therefore, the slow cleavage rate and limited product release prevent or greatly reduce subsequent turnover. Nevertheless, the time-course of product formation approximates to a straight line for 90 min (apparent initial velocity), but we show that this linear phase is due to the slow single-turnover rate constant and does not indicate steady-state multiple turnover. Finally, our data ruled out the possibility that there were large amounts of inactive proteins or dead-end complexes in the assay. Most of complexes initially formed were active although dramatically slow.

Citing Articles

Foamy Virus Integrase in Development of Viral Vector for Gene Therapy.

Kim J, Lee G, Shin C J Microbiol Biotechnol. 2020; 30(9):1273-1281.

PMID: 32699199 PMC: 9728412. DOI: 10.4014/jmb.2003.03046.


Consensus Integrase of a New HIV-1 Genetic Variant CRF63_02A1.

Agapkina Y, Pustovarova M, Korolev S, Zyryanova D, Ivlev V, Totmenin A Acta Naturae. 2019; 11(1):14-22.

PMID: 31024744 PMC: 6475865.


Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.

Hassounah S, Liu Y, Quashie P, Oliveira M, Moisi D, Brenner B J Virol. 2015; 89(23):12002-13.

PMID: 26378179 PMC: 4645305. DOI: 10.1128/JVI.02131-15.


Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.

Quashie P, Oliviera M, Veres T, Osman N, Han Y, Hassounah S J Virol. 2015; 89(6):3163-75.

PMID: 25552724 PMC: 4337543. DOI: 10.1128/JVI.03353-14.


Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.

Quashie P, Mesplede T, Han Y, Veres T, Osman N, Hassounah S Antimicrob Agents Chemother. 2013; 57(12):6223-35.

PMID: 24080645 PMC: 3837891. DOI: 10.1128/AAC.01835-13.